Enzalutamide 40 Mg Cipla 40 mg Capsule
PDF Leaflet Revision Date: 07 February 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of metastatic castration-resistant prostate cancer in adult men.
Dosage (summary)
160 mg (four 40 mg capsules) orally once daily.
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in women; potential reproductive toxicity in males.
Key Drug Interactions
- CYP2C8 inhibitors/inducers
- Warfarin
- CYP3A4 inhibitors/inducers
Contraindications
- Hypersensitivity to enzalutamide
- Women
Common side effects
- Fatigue
- Hot flush
- Headache
- Fractures
- Hypertension
Counselling Points
- Take capsules whole with water
- Use contraception during treatment
- Monitor for signs of seizures
Serious warnings
- Risk of seizure
- Posterior reversible encephalopathy syndrome
Important Disclaimer
The Enzalutamide 40 Mg Cipla 40 mg Capsule professional information leaflet below is the property of Cipla Medpro and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
